Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04515238
Title Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)
Acronym CLL2-BZAG
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors German CLL Study Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Hamatologische/Onkologische Gemeinschaftspraxis Augsburg 86150 Germany Details
Onkologische Schwerpunktpraxis Esslingen 73728 Germany Details
Evangelische Krankenhaus Hamm Hamm 59063 Germany Details
Universitaetskliniken des Saarlandes Homburg 66424 Germany Details
Universitaetsklinikum Schleswig-Holstein Campus Kiel Kiel 24105 Germany Details
Universitätsklinik Köln Köln 50937 Germany Details
Klinikum Rechts der Isar - Technische Universitaet Muenchen Munich 81675 Germany Details
Stauferklinikum Schwaebisch-Gmuend Mutlangen 73557 Germany Details
KH Kliniken Maria Hilf Mönchengladbach 41063 Germany Details
Universitätsklinik Ulm Ulm 89081 Germany Details
Hämatologisch Onkologische Schwerpunktpraxis Würzburg 97080 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field